China Resources Sanjiu Medical & Pharmaceutical (000999) Stock Price, Fundamentals & Analysis

What 000999 does

China Resources Sanjiu Medical & Pharmaceutical (000999) is a Shenzhen-listed stock in the Healthcare sector, specifically in the Drug Manufacturers – Specialty & Generic industry. The company researches, produces, and sells pharmaceutical products and health consumer goods in China and internationally. Its portfolio includes over-the-counter remedies for colds, flu, skin, gastrointestinal, cough, orthopedics, and pediatrics, as well as prescription drugs in areas such as anti-tumor, cardiovascular and cerebrovascular, digestive, and anti-infective treatments. It also offers Chinese medicine health products, vitamins, minerals, protein powder, collagen, probiotics, health foods, and formula granules, plus related health services. The firm, incorporated in 1999 and headquartered in Shenzhen, China, is a subsidiary of China Resources Pharmaceutical Group Limited and was formerly known as Sanjiu Pharmaceutical Co., Ltd.

Key numbers explained

• 23.39 CNY is the current share price, the amount you would pay for one share right now.
• The trailing P/E ratio of 11.9 shows how much the market is willing to pay per unit of recent earnings; a lower P/E ratio can suggest a more conservative valuation relative to current earnings.
• The forward P/E ratio of 9.6 uses expected future earnings, offering a look at how the market prices the company’s anticipated profitability.
• Dividend yield of 5.5% indicates the annual dividend payment as a percentage of the current share price, a common measure for income-focused investors.
• The ex-dividend date of May 29, 2026 is the cutoff: you must own the stock before this date to receive the next dividend.
• 53% of earnings paid out as dividends shows the proportion of profit returned to shareholders, with the remainder typically kept for reinvestment or reserves.
• Beta of -0.02 suggests the stock’s price movement has a very slight negative correlation with the broader market, though this figure can be sensitive to the measurement period.
• Market cap of 38.93 mld. CNY reflects the total market value of all outstanding shares, a basic measure of the company’s size.

What to watch

• Revenue growth, which is currently -13.5% year over year, can signal shifts in demand or competitive pressure within the pharmaceutical sector.
• Profit margin of 10.3% and operating margin of 13.1% are useful for comparing the company’s cost control and pricing power with peers such as Hualan Biological Engineering (002007) or Yunnan Baiyao Group (000538).
• The debt-to-equity ratio of 11.5% indicates a relatively low level of debt compared to shareholder equity, which can affect financial risk.
• The 52-week price range of 21,6 – 30,65 and the -17.1% price change over the last 52 weeks show the stock’s recent volatility and trend.
• As a subsidiary of China Resources Pharmaceutical Group Limited, the company’s strategy may be influenced by broader group decisions and cross-shareholding dynamics within the Shenzhen Stock Exchange stocks universe.